|
1
|
Ito Y, Nikiforov YE, Schlumberger M and
Vigneri R: Increasing incidence of thyroid cancer: Controversies
explored. Nat Rev Endocrinol. 9:178–184. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG
and Lee JS: Cancer statistics in Korea: Incidence, mortality,
survival and prevalence in 2010. Cancer Res Treat. 45:1–14. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ito Y, Fukushima M, Higashiyama T, Kihara
M, Takamura Y, Kobayashi K, Miya A and Miyauchi A: Incidence and
predictors of right paraesophageal lymph node metastasis of N0
papillary thyroid carcinoma located in the right lobe. Endocr J.
60:389–392. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Joshi P, Nair S, Nair D and Chaturvedi P:
Incidence of occult papillary carcinoma of thyroid in Indian
population: Case series and review of literature. J Cancer Res
Ther. 10:693–695. 2014.PubMed/NCBI
|
|
5
|
Wang J, Gao L, Song C and Xie L: Incidence
of metastases from 524 patients with papillary thyroid carcinoma in
cervical lymph nodes posterior to the sternoclavicular joint (level
VIa): Relevance for endoscopic thyroidectomy. Surgery.
159:1557–1564. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhu J, Wang X, Zhang X, Li P and Hou H:
Clinicopathological features of recurrent papillary thyroid cancer.
Diagn Pathol. 10:962015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu X, Ouyang D, Li H, Zhang R, Lv Y, Yang
A and Xie C: Papillary thyroid cancer: Dual-energy spectral CT
quantitative parameters for preoperative diagnosis of metastasis to
the cervical lymph nodes. Radiology. 275:167–176. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang YZ, Qin F, Han ZG, Liu Q, Zhou L and
Wang YW: Prognostic significance of DLL4 expression in papillary
thyroid cancer. Eur Rev Med Pharmacol Sci. 19:2901–2905.
2015.PubMed/NCBI
|
|
9
|
Zhou SF, Hu SY, Ma L, Miao L and Mao WZ:
Correlations between papillary thyroid cancer and peripheral blood
levels of matrix metalloproteinase-2, matrix metalloproteinase-9,
tissue inhibitor of metalloproteinase-1, and tissue inhibitor of
metalloproteinase-2. Chin Med J (Engl). 126:1925–1929.
2013.PubMed/NCBI
|
|
10
|
Zhu Y, Wang C, Zhang GN, Shi Y, Xu SQ, Jia
SJ and He R: Papillary thyroid cancer located in malignant struma
ovarii with omentum metastasis: A case report and review of the
literature. World J Surg Oncol. 14:172016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shi RL, Qu N, Liao T, Wang YL, Wang Y, Sun
GH and Ji QH: Expression, clinical significance and mechanism of
Slit2 in papillary thyroid cancer. Int J Oncol. 48:2055–2062. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shi RL, Qu N, Liao T, Wei WJ, Lu ZW, Ma B,
Wang YL and Ji QH: Relationship of body mass index with BRAF
(V600E) mutation in papillary thyroid cancer. Tumour Biol.
37:8383–8390. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shi X, Liu R, Basolo F, Giannini R, Shen
X, Teng D, Guan H, Shan Z, Teng W, Musholt TJ, et al: Differential
clinicopathological risk and prognosis of major papillary thyroid
cancer variants. J Clin Endocrinol Metab. 101:264–274. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Su X, Li Z, He C, Chen W, Fu X and Yang A:
Radiation exposure, young age, and female gender are associated
with high prevalence of RET/PTC1 and RET/PTC3 in papillary thyroid
cancer: A meta-analysis. Oncotarget. 7:16716–16730. 2016.PubMed/NCBI
|
|
15
|
Gao B, Tian W, Jiang Y, Zhang X, Zhao J,
Zhang S, Chen J and Luo D: Peri-operative treatment of giant
nodular goiter. Int J Med Sci. 9:778–785. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tan Z, Ge MH, Zheng CM, Wang QL, Nie XL
and Jiang LH: The significance of Delphian lymph node in papillary
thyroid cancer. Asia Pac J Clin Oncol. 13:e389–e393. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ma YJ, Deng XL and Li HQ:
BRAF(V600E) mutation and its association with
clinicopathological features of papillary thyroid microcarcinoma: A
meta-analysis. J Huazhong Univ Sci Technolog Med Sci. 35:591–599.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lu ZZ, Zhang Y, Wei SF, Li DS, Zhu QH, Sun
SJ, Li M and Li LI: Outcome of papillary thyroid microcarcinoma:
Study of 1,990 cases. Mol Clin Oncol. 3:672–676. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Qu N, Zhang L, Ji QH, Chen JY, Zhu YX, Cao
YM and Shen Q: Risk factors for central compartment lymph node
metastasis in papillary thyroid microcarcinoma: A meta-analysis.
World J Surg. 39:2459–2470. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang LY, Liu ZW, Liu YW, Gao WS and Zheng
CJ: Risk factors for nodal metastasis in cN0 papillary thyroid
microcarcinoma. Asian Pac J Cancer Prev. 16:3361–3363. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang L, Liu Z, Liu Y, Gao W and Zheng C:
The clinical prognosis of patients with cN0 papillary thyroid
microcarcinoma by central neck dissection. World J Surg Oncol.
13:1382015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Park YJ, Kim YA, Lee YJ, Kim SH, Park SY,
Kim KW, Chung JK, Youn YK, Kim KH, Park DJ and Cho BY: Papillary
microcarcinoma in comparison with larger papillary thyroid
carcinoma in BRAF(V600E) mutation, clinicopathological features,
and immunohistochemical findings. Head Neck. 32:38–45.
2010.PubMed/NCBI
|
|
23
|
Arora N, Turbendian HK, Kato MA, Moo TA,
Zarnegar R and Fahey TJ III: Papillary thyroid carcinoma and
microcarcinoma: Is there a need to distinguish the two? Thyroid.
19:473–477. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Batistatou A, Charalabopoulos K, Nakanishi
Y, Vagianos C, Hirohashi S, Agnantis NJ and Scopa CD: Differential
expression of dysadherin in papillary thyroid carcinoma and
microcarcinoma: Correlation with E-cadherin. Endocr Pathol.
19:197–202. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Antonaci A, Consorti F, Mardente S,
Natalizi S, Giovannone G and Della Rocca C: Survivin and cyclin D1
are jointly expressed in thyroid papillary carcinoma and
microcarcinoma. Oncol Rep. 20:63–67. 2008.PubMed/NCBI
|
|
26
|
Kandogan T, Erkan N and Vardar E:
Papillary carcinoma arising in a thyroglossal duct cyst with
associated microcarcinoma of the thyroid and without cervical lymph
node metastasis: A case report. J Med Case Rep. 2:422008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Barbaro D, Simi U, Meucci G, Lapi P,
Orsini P and Pasquini C: Thyroid papillary cancers: Microcarcinoma
and carcinoma, incidental cancers and non-incidental cancers-are
they different diseases? Clin Endocrinol (Oxf). 63:577–581. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schneider DF and Chen H: New developments
in the diagnosis and treatment of thyroid cancer. CA Cancer J Clin.
63:374–394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Romero-Rojas A, Cuervo-Martínez J,
Osorio-Arango K and Olaya N: Histological variants and prognostic
factors of papillary thyroid carcinoma at the Colombian Instituto
Nacional de Cancerologia, 2006–2012. Biomedica. 35:429–436. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sak SD: Variants of papillary thyroid
carcinoma: Multiple faces of a familiar tumor. Turk Patoloji Derg.
31 Suppl 1:S34–S47. 2015.
|
|
32
|
Lee JH, Shin JH, Lee HW, Oh YL, Hahn SY
and Ko EY: Sonographic and cytopathologic correlation of papillary
thyroid carcinoma variants. J Ultrasound Med. 34:1–15. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Song Q, Wang D, Lou Y, Li C, Fang C, He X
and Li J: Diagnostic significance of CK19, TG, Ki67 and galectin-3
expression for papillary thyroid carcinoma in the northeastern
region of China. Diagn Pathol. 6:1262011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gong L, Chen P, Liu X, Han Y, Zhou Y,
Zhang W, Li H, Li C and Xie J: Expressions of D2-40, CK19,
galectin-3, VEGF and EGFR in papillary thyroid carcinoma. Gland
Surg. 1:25–32. 2012.PubMed/NCBI
|
|
35
|
Liu Z, Yu P, Xiong Y, Zeng W, Li X,
Maiaiti Y, Wang S, Song H, Shi L, Liu C, et al: Significance of
CK19, TPO, and HBME-1 expression for diagnosis of papillary thyroid
carcinoma. Int J Clin Exp Med. 8:4369–4374. 2015.PubMed/NCBI
|
|
36
|
Laco J, Ryska A, Cap J and Celakovský P:
Expression of galectin-3, cytokeratin 19, neural cell adhesion
molecule and E-cadhedrin in certain variants of papillary thyroid
carcinoma. Cesk Patol. 44:103–107. 2008.PubMed/NCBI
|
|
37
|
Nasr MR, Mukhopadhyay S, Zhang S and
Katzenstein AL: Absence of the BRAF mutation in HBME1+
and CK19+ atypical cell clusters in Hashimoto
thyroiditis: Supportive evidence against preneoplastic change. Am J
Clin Pathol. 132:906–912. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lamba Saini M, Weynand B, Rahier J, Mourad
M, Hamoir M and Marbaix E: Cyclin D1 in well differentiated thyroid
tumour of uncertain malignant potential. Diagn Pathol. 10:322015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
de Oliveira JT, Ribeiro C, Barros R, Gomes
C, de Matos AJ, Reis CA, Rutteman GR and Gärtner F: Hypoxia
up-regulates galectin-3 in mammary tumor progression and
metastasis. PloS One. 10:e01344582015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ma H, Yan J, Zhang C, Qin S, Qin L, Liu L,
Wang X and Li N: Expression of papillary thyroid
carcinoma-associated molecular markers and their significance in
follicular epithelial dysplasia with papillary thyroid
carcinoma-like nuclear alterations in Hashimoto's thyroiditis. Int
J Clin Exp Pathol. 7:7999–8007. 2014.PubMed/NCBI
|
|
41
|
Tang W, Huang C, Tang C, Xu J and Wang H:
Galectin-3 may serve as a potential marker for diagnosis and
prognosis in papillary thyroid carcinoma: A meta-analysis.
OncoTargets Ther. 9:455–460. 2016. View Article : Google Scholar
|
|
42
|
Gweon HM, Kim JA, Youk JH, Hong SW, Lim
BJ, Yoon SO, Park YM and Son EJ: Can galectin-3 be a useful marker
for conventional papillary thyroid microcarcinoma? Diagn
Cytopathol. 44:103–107. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Londero SC, Godballe C, Krogdahl A,
Bastholt L, Specht L, Sørensen CH, Pedersen HB, Pedersen U and
Christiansen P: Papillary microcarcinoma of the thyroid gland: Is
the immunohistochemical expression of cyclin D1 or galectin-3 in
primary tumour an indicator of metastatic disease? Acta Oncol.
47:451–457. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dunđerović D, Lipkovski JM, Boričic I,
Soldatović I, Božic V, Cvejić D and Tatić S: Defining the value of
CD56, CK19, galectin 3 and HBME-1 in diagnosis of follicular cell
derived lesions of thyroid with systematic review of literature.
Diagn Pathol. 10:1962015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tong J, Wang Y and Da JP: Usefulness of
CK19, HBME-1 and galectin-3 expressions in differential diagnosis
of thyroid papillary microcarcinoma from benign lesions. Zhonghua
Zhong Liu Za Zhi. 33:599–604. 2011.(In Chinese). PubMed/NCBI
|
|
46
|
Caballero Y, López-Tomassetti EM, Favre J,
Santana JR, Cabrera JJ and Hernández JR: The value of
thyroperoxidase as a prognostic factor for differentiated thyroid
cancer-a long-term follow-up study. Thyroid Res. 8:122015.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu Z, Li X, Shi L, Maimaiti Y, Chen T, Li
Z, Wang S, Xiong Y, Guo H, He W, et al: Cytokeratin 19,
thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive
behavior of papillary thyroid carcinoma. Int J Clin Exp Med.
7:2304–2308. 2014.PubMed/NCBI
|
|
48
|
Yang QX, Shao CK, Feng ZY, Huang BQ, Han
AJ, Xiong M, Zhao WL and Wu TT: Detection of cytokeratin 19 and
thyroperoxidase expressions in the diagnosis of thyroid diseases.
Di Yi Jun Yi Da Xue Xue Bao. 25:678–681. 2005.(In Chinese).
PubMed/NCBI
|
|
49
|
Bizzarro T, Martini M, Marrocco C, D'Amato
D, Traini E, Lombardi CP, Pontecorvi A, Fadda G, Larocca LM and
Rossi ED: The role of CD56 in thyroid fine needle aspiration
cytology: A pilot study performed on liquid based cytology. PloS
One. 10:e01329392015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Scarpino S, Di Napoli A, Melotti F,
Talerico C, Cancrini A and Ruco L: Papillary carcinoma of the
thyroid: Low expression of NCAM (CD56) is associated with
downregulation of VEGF-D production by tumour cells. J Pathol.
212:411–419. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhou Y, Jiang HG, Lu N, Lu BH and Chen ZH:
Expression of ki67 in papillary thyroid microcarcinoma and its
clinical significance. Asian Pac J Cancer Prev. 16:1605–1608. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lubitz CC, Economopoulos KP, Pawlak AC,
Lynch K, Dias-Santagata D, Faquin WC and Sadow PM: Hobnail variant
of papillary thyroid carcinoma: An institutional case series and
molecular profile. Thyroid. 24:958–965. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Clinckspoor I, Hauben E, Verlinden L, Van
den Bruel A, Vanwalleghem L, Vander Poorten V, Delaere P, Mathieu
C, Verstuyf A and Decallonne B: Altered expression of key players
in vitamin D metabolism and signaling in malignant and benign
thyroid tumors. J Histochem Cytochem. 60:502–511. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Huang Y, Dong W, Li J, Zhang H, Shan Z and
Teng W: Differential expression patterns and clinical significance
of estrogen receptor-α and β in papillary thyroid carcinoma. BMC
Cancer. 14:3832014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Rossi M, Buratto M, Tagliati F, Rossi R,
Lupo S, Trasforini G, Lanza G, Franceschetti P, Bruni S, Degli
Uberti E and Zatelli MC: Relevance of BRAF(V600E) mutation testing
versus RAS point mutations and RET/PTC rearrangements evaluation in
the diagnosis of thyroid cancer. Thyroid. 25:221–228. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Koochak A, Rakhshani N, Karbalaie Niya MH,
Tameshkel FS, Sohrabi MR, Babaee MR, Rezvani H, Bahar B, Imanzade
F, Zamani F, et al: Mutation analysis of KRAS and BRAF genes in
metastatic colorectal cancer: A first large scale study from Iran.
Asian Pac J Cancer Prev. 17:603–608. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Gertz RJ, Nikiforov Y, Rehrauer W,
McDaniel L and Lloyd RV: Mutation in BRAF and other members of the
MAPK pathway in papillary thyroid carcinoma in the pediatric
population. Arch Pathol Lab Med. 140:134–139. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kowalska A, Walczyk A, Kowalik A, Pałyga
I, Trybek T, Kopczyński J, Kajor M, Chrapek M, Pięciak L, Chłopek
M, et al: Increase in papillary thyroid cancer incidence is
accompanied by changes in the frequency of the BRAF V600E mutation:
A single-institution study. Thyroid. 26:543–551. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Sun Y, Shi C, Shi T, Yu J and Li Z:
Correlation between the BRAF(v600E) gene mutation and factors
influencing the prognosis of papillary thyroid microcarcinoma. Int
J Clin Exp Med. 8:22525–22528. 2015.PubMed/NCBI
|
|
60
|
Li J, Zhang S, Zheng S, Zhang D and Qiu X:
The BRAF V600E mutation predicts poor survival outcome in patients
with papillary thyroid carcinoma: A meta analysis. Int J Clin Exp
Med. 8:22246–22253. 2015.PubMed/NCBI
|
|
61
|
Fu QF, Pan PT, Zhou L, Liu XL, Guo F, Wang
L and Sun H: Clinical significance of preoperative detection of
serum p53 antibodies and BRAF(V600E) mutation in patients with
papillary thyroid carcinoma. Int J Clin Exp Med. 8:21327–21334.
2015.PubMed/NCBI
|
|
62
|
Kowalska A, Kowalik A, Pałyga I, Walczyk
A, Gąsior-Perczak D, Kopczyński J, Lizis-Kolus K, Szyska-Skrobot D,
Hurej S, Radowicz-Chil A, et al: The usefulness of determining the
presence of BRAF V600E mutation in fine-needle aspiration cytology
in indeterminate cytological results. Endokrynol Pol. 67:41–47.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Beiša A, Beiša V, Stoškus M, Ostanevičiūtė
E, Griškevičius L and Strupas K: The value of the repeated
examination of BRAF V600E mutation status in diagnostics of
papillary thyroid cancer. Endokrynol Pol. 67:35–40. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Tan J: Perianal melanoma with a BRAF gene
mutation in a young Portuguese Roma native. BMJ Case Rep.
2016:bcr20152127722016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zou M, Baitei EY, Alzahrani AS, BinHumaid
FS, Alkhafaji D, Al-Rijjal RA, Meyer BF and Shi Y: Concomitant RAS
RET/PTC, or BRAF mutations in advanced stage of papillary thyroid
carcinoma. Thyroid. 24:1256–1266. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Henderson YC, Shellenberger TD, Williams
MD, El-Naggar AK, Fredrick MJ, Cieply KM and Clayman GL: High rate
of BRAF and RET/PTC dual mutations associated with recurrent
papillary thyroid carcinoma. Clin Cancer Res. 15:485–491. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Li F, Chen G, Sheng C, Gusdon AM, Huang Y,
Lv Z, Xu H, Xing M and Qu S: BRAFV600E mutation in papillary
thyroid microcarcinoma: A meta-analysis. Endocr Relat Cancer.
22:159–168. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Syrenicz A, Koziołek M, Ciechanowicz A,
Sieradzka A, Bińczak-Kuleta A and Parczewski M: New insights into
the diagnosis of nodular goiter. Thyroid Res. 7:62014. View Article : Google Scholar : PubMed/NCBI
|
